GlassScriptPhysician profile
Don W Roberts
NPI 1780755918
$8,418.42
in general payments reported to CMS, 2019-2025
34 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $1,049 · 2021: $1,494 · 2022: $1,242 · 2023: $1,430 · 2024: $1,098 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,236.04 |
| Education | $108.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,581.52 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Janssen Biotech, INC. | $959.17 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $897.20 | 2019-2024 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $626.07 | 2019-2024 | Entyvio |
| Daiichi Sankyo INC. | $462.42 | 2019-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $377.64 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $307.34 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $278.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $223.79 | 2019-2023 | Rebyota |
| Evoke Pharma, INC. | $205.44 | 2020-2024 | Gimoti |
| Intercept Pharmaceuticals, INC. | $197.87 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $195.53 | 2022-2024 | Dupixent |
| Genzyme Corporation | $167.59 | 2023-2024 | |
| Pfizer INC. | $154.74 | 2019-2024 | |
| Gilead Sciences, INC. | $115.26 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $91.33 | 2019-2023 | Sutab |
| Redhill Biopharma INC. | $90.75 | 2020-2024 | Talicia |
| Boston Scientific Corporation | $62.61 | 2019-2025 | Orcapod, Spyglass |
| Vivus LLC | $53.94 | 2021-2022 | |
| Allergan, INC. | $46.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.34 | 2023-2024 | |
| Alfasigma USA, INC. | $32.88 | 2020 | |
| Phathom Pharmaceuticals, INC. | $30.46 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $24.00 | 2021 | |
| Aimmune Therapeutics, INC. | $22.99 | 2024 | |
| Concordia Pharmaceuticals INC. | $22.95 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.91 | 2025 | Acthar |
| Echosens North America, INC. | $22.75 | 2020 | |
| Lilly USA, LLC | $22.10 | 2025 | Omvoh |
| Ucb, INC. | $18.93 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.98 | 2025 | Iqirvo |
| Astrazeneca Pharmaceuticals LP | $16.52 | 2020 | |
| Mauna Kea Technologies, INC. | $12.06 | 2022-2023 | |
| Dova Pharmaceuticals | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.